Communications and Marketing

Armed antibodies for cancer immunotherapy: DKFZ and DKTK scientists granted patent for innovative antibody design

No. 59 | 20/12/2019 | by AM

Scientists from the German Cancer Consortium (DKTK) and the German Cancer Research Center (DKFZ) at Tübingen University Hospital have managed to attach immunostimulatory cytokines to cancer-specific antibodies for the first time in such a way that they activate the immune response against cancer without causing a dangerous overreaction by the immune system. The research team has now been granted a European patent for the method to enable them to produce the modified cytokines on a large scale and subsequently test them in clinical trials. A license and cooperation agreement has been signed with the South Korean biotech company ABL Bio on the production of two substances of clinical quality.
In the German Cancer Consortium (DKTK), the German Cancer Research Center (DKFZ) in Heidelberg, DKTK's core center, cooperates on a long-term basis with certified German university hospitals specialized in oncology.

Production of immunotherapeutics according to clinical standards in the GMP center of the University Tübingen.
© G. Jung / University Tübingen

Cytokines such as interleukins and interferons are endogenous messenger proteins that stimulate the immune system to fight infection and tumors. Researchers have been trying for decades to use the immunostimulatory properties of cytokines to treat cancer. Progress has been made in recent years in infiltrating tumors with cytokines by attaching them to antibodies that target cancer-specific proteins. One of the problems in the clinical development of these immunocytokines are the severe side effects caused by uncontrolled immune activation, however. "Cytokines are toxic in larger quantities and activation is unfortunately nonspecific if they are fused to antibodies in the blood without being attached to the tumor," explained DKTK Professor and physician Helmut Salih, head of the Clinical Cooperation Unit Translational Immunology at Tübingen University Hospital. "This can lead to a real cytokine 'storm', which causes fever, exhaustion and sometimes even cardiovascular shock."

Salih and his colleague Gundram Jung, head of the Experimental Antibody Therapy section at Tübingen University, thus designed a new, modified form of immunocytokines (MICs). They attached interleukin IL-15 to an antibody that recognizes a surface molecule such as CD19 on leukemia cells. The key thing about the new method are the genetically modified properties of the IL-15, which acts like a kind of security lock. In the MICs, the IL-15 is genetically modified so that it cannot bind to the immune system's killer cells and activate them against cancer until the antibody binds to the cancer cell.

Salih and his colleague Gundram Jung, head of the Experimental Antibody Therapy section at Tübingen University, thus designed a new, modified form of immunocytokines (MICs). They attached interleukin IL-15 to an antibody that recognizes a surface molecule such as CD19 on leukemia cells. The key thing about the new method are the genetically modified properties of the IL-15, which acts like a kind of security lock. In the MICs, the IL-15 is genetically modified so that it cannot bind to the immune system's killer cells and activate them against cancer until the antibody binds to the cancer cell.

"Even with high doses of MICs, we see very little untargeted and hence undesirable activation of killer cells, which in contrast we always see with unmodified immunocytokines even in smaller doses," Salih commented. "That means that we can administer higher and hence effective doses without having to worry about dramatic side effects." In mice and cell culture experiments, the anti-tumor effect of the new immunotherapeutic agents was so promising that several pharmaceutical companies have already registered their interest. An initial license and cooperation agreement has now been signed with the South Korean biotech company ABL Bio on the production of two MICs.

In the present preclinical studies on cell cultures and mice, the researchers tested MICs against leukemia, lymphomas, and various solid tumors. "But in principle, the newly patented method can be used to equip any cancer-specific antibody with the 'safe' IL-15 and make it more powerful," Gundram Jung emphasized, adding that this made treatment with immunocytokines conceivable in patients with very different types of cancer. Over the next 18 months, the researchers and ABL Bio will be concentrating on production of the first two MICs of clinical quality and characterizing their properties in detail. This is to be followed by clinical studies conducted in the Clinical Cooperation Unit Translational Immunology at the DKTK partner site in Tübingen and at other DKTK partner sites. "We are very pleased to have found a really suitable partner from among the many interested parties with whom we can work hard on developing the new immunotherapeutic agents so that we can help cancer patients as soon as possible," Helmut Salih remarked.

An image for the press release can be found at:
www.dkfz.de/de/presse/pressemitteilungen/2019/bilder/Herstellung-Immuntherapeutika.jpg 
Image caption:
Production of immunotherapeutics according to clinical standards in the GMP center of the University Tübingen.

Note on use of images related to press releases
Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: "Source: G. Jung / University Tübingen".
Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ's Press Office (phone: ++49-(0)6221 42 2854, E-mail: presse@dkfz.de). Any commercial use is prohibited.

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. At DKFZ, more than 1,300 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. DKFZ’s Cancer Information Service (KID) provides individual answers to all questions about cancer for patients, the general public, and health care professionals. Jointly with partners from Heidelberg University Hospital, DKFZ runs the National Center for Tumor Diseases (NCT) located in Heidelberg and Dresden, and, also in Heidelberg, the Hopp Children’s Cancer Center (KiTZ). In the German Cancer Consortium (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center at the NCT and DKTK sites is an important contribution to the endeavor of translating promising approaches from cancer research into the clinic in order to improve the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS